|
| Press Releases |
|
 |
|
| Tuesday, March 23, 2021 |
|
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
| Monday, March 22, 2021 |
|
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
|
Eisai Awarded The New Diversity Management Selection 100 |
| Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program. more info >> |
|
| Wednesday, March 17, 2021 |
|
|
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders |
| Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells. more info >> |
|
| Tuesday, March 16, 2021 |
|
|
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu |
| Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and University College London, has been selected by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). more info >> |
|
| Friday, March 12, 2021 |
|
|
Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Friday, March 5, 2021 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease |
| Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta protofibril antibody lecanemab, will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021. more info >> |
|
| Thursday, March 4, 2021 |
|
|
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya |
| Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. more info >> |
|
| Tuesday, March 2, 2021 |
|
|
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong |
| Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Monday, February 22, 2021 |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090 |
| Eisai Co., Ltd. announced that it has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor E7090, which is currently under development as an orally available novel anti-cancer agent. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sept 12, 2025 15:08 JST
|
|
|
GR Yaris "Aero performance package" Set for Japan Launch
Sept 12, 2025 14:40 JST
|
|
|
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sept 12, 2025 14:19 JST
|
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 12, 2025 13:20 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sept 12, 2025 11:00 JST
|
|
|
Among Migrating Nurses, Survey Shows High Satisfaction Rates for Those Who Use a Certified Ethical Recruiter
Sept 12, 2025 05:00 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Important High-Grade Copper and Gold Intercepts at Hat Polymetallic Deposit in Northwestern British Columbia
Sept 11, 2025 22:29 HKT/SGT
|
|
|
The 10th Belt and Road Summit concludes successfully
Sept 11, 2025 20:40 HKT/SGT
|
|
|
CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sept 11, 2025 20:37 JST
|
|
|
Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development
Sept 11, 2025 18:35 JST
|
|
|
GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sept 11, 2025 17:24 JST
|
|
|
A Sparkling New Chapter: Spritzer's First-Ever Mini-Drama Series Stars New Brand Ambassador Anna Jobling
Sept 11, 2025 16:23 HKT/SGT
|
|
|
GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sept 11, 2025 16:46 JST
|
|
|
JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban" 
Sept 11, 2025 13:00 JST
|
|
|
Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sept 11, 2025 10:35 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
